Premenstrual Disorder
More than last decade there has been mounting acceptance of premenstrual disorders, and plentiful remedies have been tried for symptom relief.More than 400 articles were recalled, only one-third of them characterized double-blind studies and just 41 of the double-blind studies associated prospectively diagnosed patients. The definition of the disorder mixed across studies, as did research design and outcome measures. Many studies did not estimate for Axis I comorbidity, which may have a indicative impact on drug response..
We experimented to do a metaanalysis of the existing double-blind, prospectively diagnosed studies, broken down by drug class and symptom reduction. After all, we could not make statistical comparisons within or across drug groups to assess efficacy of treatment for particluar symptoms due to differences in outcome-assessment measures across studies. Several promising pharmacological strategies exist to cure the patient with premenstrual dysphoric disorder. We review double-blind studies for each class of drugs, focus some open studies, and current guidelines. Additional double-blind studies with prospectively diagnosed patients are needed. Standardization of definition, design, and result measures used in this field is cardinal to enable direct correlation across studies of different treatment strategies.
Click here to read about the symptoms of PMS